Alternative Funding Programs Vs. In-Benefit Optimization: Designing a Sustainable Specialty Drug Strategy

Why It Matters

Escalating specialty drug spend threatens employer health‑plan margins and patient access; effective, compliant cost‑control mechanisms protect financial sustainability while maintaining therapy continuity.

Key Takeaways

• US drug spend hit $467B in 2024, $556B by 2026.
• AFPs tap manufacturer assistance to lower out‑of‑pocket costs.
• In‑benefit optimization uses analytics to cut waste in existing plans.
• Guardrails ensure continuity, compliance, and prescriber workflow ease.
• Hybrid platforms layer AFPs and optimization for sustainable margins.

Pulse Analysis

The specialty drug market is expanding faster than most health‑plan budgets can absorb. In 2024, U.S. prescription drug spending topped $467 billion, and forecasts suggest it will top $556 billion by the end of 2026. This trajectory intensifies pressure on employers and PBMs to find ways to keep high‑cost therapies affordable without sacrificing clinical outcomes. The challenge is not merely the headline price tag; it lies in the concentration of spend on a limited set of high‑impact drugs that can destabilize benefit designs if left unchecked.

Alternative funding programs (AFPs) and in‑benefit optimization represent two distinct, technology‑driven pathways to address this dilemma. AFPs connect members to manufacturer patient‑assistance programs, copay‑offsets, and other external resources, effectively lowering out‑of‑pocket costs for targeted specialty therapies. In‑benefit optimization, by contrast, embeds advanced analytics into the existing pharmacy benefit workflow, flagging duplicate therapies, early refills, and oversupply while recommending lower‑cost formulary alternatives. Both models rely on algorithmic intelligence to identify spend concentrations, but they differ in execution—AFPs create new sourcing channels, whereas in‑benefit optimization refines the current channel.

The most resilient strategy blends the two under a single drug‑spend intelligence platform. By layering AFPs for high‑price, high‑impact drugs with system‑wide waste reduction, plan sponsors can achieve granular savings while preserving continuity of care, easing prescriber burden, and staying within regulatory bounds. Such hybrid models provide documented, defensible cost reductions that protect margins, improve member experience, and support long‑term benefit stability. As specialty drug costs continue to climb, employers that adopt this dual‑track, technology‑enabled approach will be better positioned to sustain affordable coverage and maintain competitive health‑plan offerings.